All In Biotech

Drug Trial Radar · NCT01889251

A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion

A Phase III Study of A01016 125μg Intravitreal Injection in Subjects With Symptomatic Vitreomacular Adhesion - Comparison Study to Sham Injection

Last checked: Nov 20, 2026Latest source record: Nov 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

251

Actual

Start

Jul 2013

Primary completion

Sep 2014

Study completion Sep 2014

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Jun 28, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.

Conditions

  • Symptomatic Vitreomacular Adhesion

Interventions

  • OcriplasminDrug

  • Sham injectionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects With Non-Surgical Resolution of Vitreomacular Adhesion (VMA)Time frame: Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Contact Alcon for Trial Locations

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.